ライフサイエンスコーパス: IAP

1 IAP also exhibits anti-inflammatory effects in a Toll-li

2 IAP also inhibited LPS-induced IL-1beta mRNA expression

3 IAP also upregulated autophagy-related gene expression i

4 IAP antagonists, such as Reaper, Hid, and Grim, are thou

5 IAP is a major regulator of gut mucosal permeability and

6 IAP provides user-friendly interfaces, and its core func

7 IAPs are therefore, not only gatekeepers of cell death,

8 IAPs contain one to three BIR domains that are crucial f

9 IAPs have been proposed as targets for anticancer therap

10 eeded to be treated (NNT-value) to prevent 1 IAP.

11 analyze the DNA methylation pattern of 4799 IAP LTR retrotransposons in embryonic stem, somatic and

12 sion, the risk of EOGBS in settings with 80% IAP coverage was predicted to be 0.3% (95% CI, 0-.9).

13 Systematic identification of additional IAP substrates is challenged by the heterogeneity and sh

14 AP antagonist structurally distinct from all IAP antagonists previously reported.

15 y, we uncover a unique role for BIRC3, as an IAP that is critical in GBM in response to therapy.

16 Of these, 60 of 95 (63%) had an IAP policy; 35 of 60 (58%) used microbiological screenin

17 We have identified an IAP-binding motif (IBM) at the amino terminus of NIK.

18 acts with the BIR2 domain of XIAP through an IAP-binding motif, the mutation of which impairs the ant

19 We included data on whether an IAP policy was in use, and if so whether it was based on

20 fection by pharmacological targeting with an IAP antagonist/second mitochondria-derived activator of

21 The risk of EOGBS in settings without an IAP policy was 1.1% (95% confidence interval [CI], .6%-1

22 ession of survival proteins in the Bcl-2 and IAP families and removed controls on the activation stat

23 ction of survival molecules in the Bcl-2 and IAP families, induced downstream of an IGF-1R/NFkappaB c

24 was diminished, and expression of Bcl-2 and IAP family members were down-regulated, resulting in hig

25 y, preceded by the upregulation of LINE1 and IAP transposons as well as activation of a DNA damage re

26 H4R3me2s chromatin modification on LINE1 and IAP transposons in PGCs, directly implicating this modif

27 e aimed to review GBS screening policies and IAP implementation worldwide.

28 collected from 20 patients postileostomy and IAP levels were compared between fasted and fed states.

29 Downregulation of OTUB1 promotes TWEAK- and IAP antagonist-stimulated caspase activation and cell de

30 WT and IAP-KO mice were used to examine gut barrier function an

31 biting DNA-PK reduced expression of RIP1 and IAPs in cisplatin-treated cells.

32 y consisting of histone H4, DNA-PK, RIP1 and IAPs that attenuates ROS-mediated apoptosis, and targeti

33 umber of proapoptotic proteins to antagonize IAP function.

34 40 of 44 (91%) high-income countries had any IAP policy.

35 al expression of a selected set of pea aphid IAPs and showed that they are differentially expressed i

36 Drosophila inhibitor of apoptosis (IAP) 1 (DIAP1) is an E3 ubiquitin ligase that regulates

37 Small-molecule inhibitor of apoptosis (IAP) antagonists, called Smac mimetic compounds (SMCs),

38 in, along with other inhibitor of apoptosis (IAP) family members (cIAP1, cIAP2, and X-linked inhibito

39 redominantly in the inhibitors of apoptosis (IAP) family.

40 vin, a member of the inhibitor of apoptosis (IAP) family.

41 ion, a member of the inhibitor of apoptosis (IAP) family.

42 ting gene coding for inhibitor of apoptosis (IAP) into larvae and adults resulted in a significant kn

43 SM antagonize inhibitor of apoptosis (IAP) proteins and simultaneously induce tumor necrosis f

44 Baculovirus-encoded inhibitor of apoptosis (IAP) proteins likely evolved from their host cell IAP ho

45 unique member of the inhibitor of apoptosis (IAP) proteins that is overexpressed in numerous cancers

46 paB pathway using an inhibitor of apoptosis (IAP), AZD5582, reverses HIV/simian immunodeficiency viru

47 Inhibitors of apoptosis (IAP-like proteins; ORF016, ORF025, and ORF074) were expr

48 In insects, inhibitor-of-apoptosis (IAP) proteins act as regulatory sentinels by responding

49 Inhibitor-of-apoptosis (IAP) proteins are key regulators of the innate antiviral

50 Inhibitor-of-apoptosis (IAP) proteins, particularly cIAP1, are essential mediato

51 Survivin, an inhibitor of apoptosis (IAPs) family member, exhibited a decreased expression le

52 itory part, with 28 inhibitors of apoptosis (IAPs).

53 As IAP increased, the risk of EOGBS decreased, with a linea

54 d to a fragment-derived lead resulting in AT-IAP, a potent, orally bioavailable, dual antagonist of X

55 nked inhibitor of apoptosis, and baculoviral IAP repeat-containing 7 were all up-regulated in SPRIGHT

56 mature form (20.8 kDa) binds to baculoviral IAP repeat (BIR) domains of inhibitor of apoptosis prote

57 displacing active caspases from baculovirus IAP repeat domains in DIAP1, but can themselves become t

58 NIK interacts with the second baculovirus IAP repeat (BIR2) domain of c-IAP1 via the IBM, and this

59 ncluding the conservation of two baculovirus IAP repeat (BIR) domains and a C-terminal RING, viral IA

60 of interest that best discriminated between IAP-determined left or right dominance for language were

61 Newborn gut colonization differed in both IAP and postnatal antibiotics groups as compared to that

62 ates for epilepsy surgery and underwent both IAP and resting-state functional MR imaging as part of p

63 In contrast, in the absence of both IAPs and caspase-8, RIPK3 kinase activity and MLKL are e

64 vered that lepidopteran (moth and butterfly) IAPs, which are degraded upon baculovirus infection, are

65 oduction and consequent cell death caused by IAP depletion was attenuated by loss or inhibition of TN

66 e Beclin 1-dependent autophagy activation by IAPs described in this study.

67 r the vast majority of DALY losses caused by IAPs considered in this analysis, with impacts on par or

68 describe the identification of OTUB1 as a c-IAP-associated deubiquitinating enzyme that regulates c-

69 Through their E3 ligase activity c-IAP proteins promote ubiquitination of receptor-interact

70 The cellular inhibitor of apoptosis (c-IAP) proteins are E3 ubiquitin ligases that are critical

71 OTUB1 expression in zebrafish destabilizes c-IAP (Birc2) protein levels and disrupts fish vasculature

72 Apoptosis negative (c-IAP-2 and Bcl-xL) and positive (DR5) regulators were pot

73 Consequently, in the absence of c-IAP proteins, TNFR-mediated activation of NF-kappaB and

74 by upregulation of antiapoptotic protein (c-IAP-2) through calmodulin-dependent kinase-II activation

75 Thus, c-IAP-2 may prevent Vpr-mediated mitochondrial depolarizat

76 IAP antagonist that specifically triggers c-IAP degradation.

77 s have been developed that also target the c-IAPs and induce their degradation.

78 However, it is not clear how the c-IAPs specifically recognize and ubiquitylate NIK in the

79 NIK is brought into close proximity to the c-IAPs through a TRAF2-TRAF3 bridge where TRAF2 recruits c

80 sly shown to induce the degradation of the c-IAPs, to SM-164, a synthetic IAP antagonist that specifi

81 iota and that oral supplementation with calf IAP (cIAP) rapidly restores the normal gut flora.

82 proteins likely evolved from their host cell IAP homologs, which function as critical regulators of c

83 inhibitor of apoptosis, as well as cellular IAP-1.

84 ns Op-IAP3's requirement for native cellular IAP as a cofactor and the dispensability of caspase inhi

85 tination when bound to its targeted cellular IAP.

86 inating host IAP in such a way that cellular IAP levels and antiapoptotic activities are maintained.

87 unctioning as a protein degron, the cellular IAP leader dramatically shortened the life span of a lon

88 Thus, the leaders of cellular IAPs from diverse insects carry unique signal-responsive

89 Such signal-induced destruction of cellular IAPs is distinct from degradation caused by well-known I

90 spite their striking relatedness to cellular IAPs, including the conservation of two baculovirus IAP

91 Intrapartum antibiotic chemoprophylaxis (IAP) prevents most early-onset group B streptococcal (GB

92 ions that abrogate binding of well-conserved IAP antagonists did not affect Op-IAP3's capacity to pre

93 nique signal-responsive degrons that control IAP turnover.

94 egulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treat

95 f the K-epsilon-GG epitope recognized during IAP, here we developed a large-scale FASP method (LFASP)

96 bsence of analogous degrons in virus-encoded IAPs explains their relative stability and antiapoptotic

97 the development of unprecedented high-energy IAP sources in the near future.

98 Enteral IAP supplementation may represent a novel approach to ma

99 also bind to TEs, including the active ETn, IAP, and L1 families.

100 We found that exogenous IAP induced autophagy in intestinal epithelial cells and

101 ll-known IAP antagonists, which act to expel IAP-bound caspases.

102 show that the two most active ERV families, IAP and MusD/ETn, are major targets and are strongly inh

103 Five IAPs are specifically induced in bacteriocytes, the spec

104 strated the antiapoptotic role of these five IAPs using heterologous expression in a tractable in viv

105 etically considered multi-colour drivers for IAP generation can be realized with existing high-power

106 and a structurally novel chemical probe for IAP biology.

107 Penicillin was mostly used for IAP and the combination of penicillin and aminoglycoside

108 Furthermore, IAP supplementation improves the lipid profile in mice f

109 Animals given IAP maintained their weight, had reduced clinical severi

110 ating with unstable, autoubiquitinating host IAP in such a way that cellular IAP levels and antiapopt

111 Viral IAP-mediated preservation of the host IAP homolog capitalizes on normal IAP-IAP interactions a

112 In insects, wherein the host IAP provides a primary restriction to apoptosis, diverse

113 nction, WT mice were fasted for 48 hours +/- IAP supplementation in the drinking water.

114 udy lays the framework for investigating how IAP and autophagy may act together to control inflammato

115 However, there is no description of how IAP is used around the world.

116 my in patients with concurrent elevations in IAP and ICP can reduce ICP.

117 Furthermore, although it was found in IAP virus-like particles, it did not affect their incorp

118 There is considerable heterogeneity in IAP screening policies and coverage worldwide.

119 scence intensity of LC3 was also observed in IAP-treated tissues compared to the vehicle-treated tiss

120 Increasing IAP coverage was linearly associated with decreased risk

121 dipteran DIAP1 also conferred virus-induced IAP depletion by a caspase-independent mechanism.

122 We used Tet-inducible IAP gene expression to uncouple this process from virus-

123 All recurrent attacks of AP after an initial IAP episode were registered.

124 ere that the N-terminal leader of two insect IAPs, Spodoptera frugiperda SfIAP and Drosophila melanog

125 Interestingly, IAPs with the strongest antiapoptotic potential contain

126 Most known IAP inhibitors are selective for the BIR3 domain and bin

127 stinct from degradation caused by well-known IAP antagonists, which act to expel IAP-bound caspases.

128 ted arthritis is exacerbated in mice lacking IAPs, and is reduced by deletion of RIPK3, but not MLKL.

129 d genomes and found that they all show large IAP expansion, with new combinations of protein domains,

130 ed motifs that are not found in lepidopteran IAPs.

131 otein alone and in complex with the X-linked IAP (XIAP)-BIR2-BIR3 domains.

132 ibitor of apoptosis proteins (IAPs: X-linked IAP, cellular IAP1 and IAP2) regulate RIPK3 and MLKL ubi

133 complex with SfIAP, the native, short-lived IAP of host insect Spodoptera frugiperda.

134 tor zanamivir was therapeutic by maintaining IAP abundance and function.

135 About half of the variably methylated IAP LTRs tend to be hypomethylated in ES cells, and near

136 Furthermore, small molecule IAP antagonists can modulate spontaneous as well as TNF-

137 Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical t

138 equent optimization gave a potent nonalanine IAP antagonist structurally distinct from all IAP antago

139 f the host IAP homolog capitalizes on normal IAP-IAP interactions and is likely the result of viral I

140 Up to 50% to 75% of IAP may be due to microlithiasis, which is undetectable

141 The administration of IAP or the antiviral neuraminidase inhibitor zanamivir w

142 e regulated by differential amplification of IAP antagonists, unique caspase adaptor proteins, and mu

143 s a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical devel

144 s (over 18 years) with their first attack of IAP.

145 y of cancers has prompted the development of IAP antagonists as potential antitumor therapies.

146 The diagnosis of IAP was based on the exclusion of common etiological rea

147 viral escape mechanisms and the dynamics of IAP action has the potential to facilitate the developme

148 The profound negative effect of IAP antagonists on T-cell immunity was partially linked

149 To study the effect of IAP supplementation on starvation-induced gut barrier dy

150 research is needed regarding the effects of IAP on other cancers and the effects of different types

151 may mediate the anti-inflammatory effects of IAP.

152 t to induction of apoptosis by expression of IAP-antagonists, DNA-damaging agents and even knockdown

153 letely shared, indicating novel functions of IAP antagonists and consequences of c-IAP1/2 degradation

154 w this approach can enable the generation of IAP with the available high-energy kHz-repetition-rate Y

155 We compared the impact of IAP, postnatal antibiotics, or their combination on the

156 es, it did not affect their incorporation of IAP RNA, primer tRNAPhe (phenylalanine tRNA), or IAP Gag

157 The loss of IAP expression is associated with decreased expression o

158 ike receptor 4 (TLR4)-dependent mechanism of IAP desialylation with accumulation of the IAP substrate

159 significant correlation between the onset of IAP expression and halted IFN-beta expression in cells w

160 ow-up of 36 (5-58) months, the recurrence of IAP was significantly higher in the control group than i

161 CC can effectively prevent the recurrence of IAP when all other possible etiologies of pancreatitis a

162 es of solid fuels, oral and dermal routes of IAP exposure, genetic and epigenetic mechanisms, and gen

163 The effect size of IAP was comparable to that caused by postnatal antibioti

164 of this method was assessed against that of IAP by using a variety of thresholds.

165 For validation of IAP, we performed an example experiment that contains 33

166 Ablation or antagonism of IAPs potently suppressed TNF- or RIPK1-induced proinflam

167 The corresponding contributions of IAPs to infectious disease outcomes are relatively unexp

168 umulation of cellular ROS and degradation of IAPs (cIAP1 and XIAP).

169 mplex that may be related to optimization of IAPs binding.

170 Overexpression of IAPs occurs in various cancers and has been associated w

171 , along with increased retrotransposition of IAPs.

172 The prominent role of IAPs in controlling cell death and their overexpression

173 To define the role of IAPs in myelopoiesis, we generated a mouse with cIAP1, c

174 In this study, we analyzed the role of IAPs in T-cell immunity during lymphocytic choriomeningi

175 Normally, SETDB1 maintains silencing of IAPs, but in the absence of DNMT1, prolonged binding of

176 nique samples, we identify BIRC3 is the only IAP whose differential expression is associated with lon

177 RNA, primer tRNAPhe (phenylalanine tRNA), or IAP Gag.

178 We administered either vehicle or IAP (100 U/ml) in drinking water for 14 days in C57BL/6

179 Oral IAP supplementation protected mice from antibiotic-assoc

180 ides) that occurs with dietary fat, and oral IAP supplementation prevents as well as reverses metabol

181 We postulate that oral IAP supplementation could represent a novel therapy to p

182 We hypothesized that oral IAP supplementation would protect against antibiotic-ass

183 hanistically distinct from that of known pan-IAP inhibitors.

184 nt attacks of idiopathic acute pancreatitis (IAP).

185 develop an Incentivized Attention Paradigm (IAP) and use it to show that macaque monkeys readily lea

186 of the endogenous intracysternal A particle (IAP) by a similar mechanism.

187 n yeast and mouse intracisternal A particle (IAP) long terminal repeat (LTR) retrotransposons in cult

188 ajor satellites, intracisternal A particles (IAPs), and imprinted genes remain relatively resistant t

189 family and intracisternal A-type particles (IAPs).

190 ncer therapy, and a number of peptidomimetic IAP antagonists have entered clinical trials.

191 s given a 24 h of inoculation access period (IAP) to inoculate CCYV on cucumber plants showed a trans

192 Intestinal alkaline phosphatase (IAP) regulates bicarbonate secretion, detoxifies lipopol

193 der enzyme, intestinal alkaline phosphatase (IAP), in preventing a high-fat-diet-induced metabolic sy

194 ecretion of intestinal alkaline phosphatase (IAP), which induces changes in the gut bacteria composit

195 learance of intestinal alkaline phosphatase (IAP).

196 re, we present Integrated Analysis Platform (IAP), an open-source framework for high-throughput plant

197 as well as 3,964 fixed and 1,986 polymorphic IAPs, in mouse.

198 We have identified >50 potential IAP substrates of both cytosolic and mitochondrial origi

199 call an 'intermediate astrocyte precursor' (IAP) located in the mantle region of the spinal cord.

200 Elevated intra-abdominal pressure (IAP) is associated with ICP elevation, and decompressive

201 ts of an intracarotid amobarbital procedure (IAP).

202 receive intrapartum antibiotic prophylaxis (IAP) to prevent sepsis in infants and 2-5% of newborn in

203 erage of intrapartum antibiotic prophylaxis (IAP), used to reduce the incidence of EOGBS.

204 s due to intrapartum antibiotic prophylaxis (IAP).

205 pulse of the inhibitor of apoptosis protein (IAP) antagonist reaper.

206 scription of inhibitor of apoptosis protein (IAP) antagonists reaper, hid and grim.

207 at maintains inhibitor of apoptosis protein (IAP) expression by release of microRNA-146a-mediated cat

208 mbers of the inhibitor of apoptosis protein (IAP) family and are key regulators of anti-apoptotic and

209 ember of the Inhibitor of Apoptosis Protein (IAP) family, is required for cancer cell survival and ov

210 ember of the inhibitor of apoptosis protein (IAP) family, regulates mitosis and chromosome segregatio

211 , also known as integrin-associated protein (IAP), is a transmembrane protein with multiple biologica

212 Inhibitors of Apoptosis Protein (IAPs) are guardian ubiquitin ligases that keep classic p

213 Inhibitors of apoptosis proteins (IAP) exert critical control on the terminal segment of a

214 mber of the inhibitor of apoptosis proteins (IAP) family, protein survivin (Sur), a ubiquitous re-org

215 ression of inhibitors of apoptosis proteins (IAP) has been implicated in drug resistance in several c

216 rough expression of IFN antagonist proteins (IAPs).

217 Inhibitor of apoptosis proteins (IAPs) are important regulators of apoptosis and pro-surv

218 he roles of inhibitor of apoptosis proteins (IAPs) in the regulation of TNF-induced cell death in the

219 Inhibitor of apoptosis proteins (IAPs) play a major role in determining whether cells und

220 domains of inhibitor of apoptosis proteins (IAPs) releasing their inhibitory effects on caspases, th

221 Inhibitors of apoptosis proteins (IAPs) were originally described as regulating apoptosis

222 ) proteins, inhibitor of apoptosis proteins (IAPs), and murine double-minute 2 (MDM2).

223 ch degrades inhibitor of apoptosis proteins (IAPs), eliminated early-stage metastases and reduced pro

224 Loss of inhibitor of apoptosis proteins (IAPs), particularly cIAP1, can promote production of tum

225 function of inhibitor of apoptosis proteins (IAPs), thereby promoting cancer cell death.

226 ists of the inhibitor of apoptosis proteins (IAPs), which activate noncanonical NF-kappaB signaling a

227 ists of the inhibitor of apoptosis proteins (IAPs).

228 in TRIF and inhibitor of apoptosis proteins (IAPs: X-linked IAP, cellular IAP1 and IAP2) regulate RIP

229 PI) to the inhibitors of apoptotic proteins (IAPs) enters cancer cells and normal cells by caveolin-d

230 m, we investigated Op-IAP3, the prototypical IAP from baculovirus OpMNPV.

231 es examined, consistent with other published IAP inhibitors.

232 Isolated attosecond pulses (IAP) generated by high-order harmonic generation are val

233 antibodies for immunoaffinity purification (IAP) and subsequent identification of ubiquitination sit

234 to apoptosis, diverse viruses trigger rapid IAP depletion that initiates caspase-mediated apoptosis,

235 ated coverage (percentage of women receiving IAP where indicated).

236 More recently, IAPs have been identified as important modulators of can

237 in distinct instability motifs that regulate IAP turnover and apoptotic consequences.

238 vity of the SfIAP RING, which also regulated IAP stability.

239 0 GBS colonized pregnant women that reported IAP coverage.

240 ed the movement of an endogenous retrovirus (IAP), our finding shed new light on this intracellular r

241 ional activation of ERVs, including CpG-rich IAP (intracisternal A particle) proviruses.

242 -responsive mechanisms by which the sentinel IAPs are actively degraded to initiate host apoptosis.

243 AVPI-bearing peptide assemblies sequestrates IAPs and releases bortezomib (BTZ), a proteasome inhibit

244 d by 3-methyladenine (3MA) or by Atg5 siRNA, IAP failed to block LPS-mediated effects.

245 SPC-IAP's high brightness (L* = 79.55), low redness (a* = 0.

246 that the isolated protein concentrates (SPC-IAP) show high protein content (69.08% d.b) as well as h

247 nisms and antagonistic partners for specific IAPs, and provide a powerful technology for labeling bin

248 In summary, IAP provides a multiple set of functionalities for impor

249 that both endogenous and orally supplemented IAP inhibits absorption of endotoxin (lipopolysaccharide

250 C34), a TLR4 signaling inhibitor, suppressed IAP-induced autophagy.

251 Surprisingly, IAP antagonism also led to spontaneous production of che

252 dation of the c-IAPs, to SM-164, a synthetic IAP antagonist that specifically triggers c-IAP degradat

253 However, the extent of a synthetic IAP antagonist's ability to mirror the transcriptional p

254 vide insight into the mechanism of synthetic IAP antagonists, furthering our understanding of their t

255 ondrial origin that bear hallmark N-terminal IAP binding motifs.

256 For the first time, we demonstrate that IAP expression is also decreased in humans who are depri

257 Finally, our data demonstrate that IAP supplementation reverses the gut barrier dysfunction

258 We tested the hypothesis that IAP may induce autophagy which may mediate the anti-infl

259 t such as a virus infection, indicating that IAP antagonists may interfere with immune responses.

260 Previously, we have shown that IAP detoxifies bacterial toxins, prevents endotoxemia, a

261 Previously, we have shown that IAP preserves the normal homeostasis of intestinal micro

262 These data indicate that IAPs not only prevent antiviral signalling prior to IFN-

263 Here, we show that IAPs are required for the production of multiple TNF-ind

264 the pro-apoptotic protease caspase-8 and the IAP ubiquitin ligases, how and when necroptosis is trigg

265 ccurred via the BIR3 domain of cIAP1 and the IAP-binding motif of C9b, but did not require proteolyti

266 gm1, Tlr4, and Lyz genes was observed in the IAP treated group compared to the vehicle treated group.

267 NA-damaging agents and even knockdown of the IAP diap1.

268 ncoded by BIRC5), the smallest member of the IAP family, has been correlated with both the control of

269 f IAP desialylation with accumulation of the IAP substrate and TLR4 ligand, lipopolysaccharide-phosph

270 Correlation with the IAP was seen in 13 of 14 (93%) prospective patients, wit

271 phosphorylation-sensitive degron within the IAP N-terminal leader.

272 The IAPs are key regulators of the apoptotic pathways and ar

273 The IAPs were first discovered in baculoviruses because of t

274 The applicability of these IAP would be widened drastically by increasing their ene

275 induction of the E3 ligase activity of this IAP family member.

276 Thus, IAPs play a major role in influencing the production of

277 Thus, IAPs play an important role in T-cell expansion and surv

278 lly reduced in LCMV-infected mice exposed to IAP antagonists.

279 loss of maternal-zygotic PRMT5 also leads to IAP upregulation.

280 pporting a role for FADD in sensitization to IAP inhibitor and death ligands.

281 Rapid response pathways that trigger IAP degradation and initiate apoptosis independent of ca

282 ot viable, and 2 mimicked features of triple IAP knockout cells in vitro.

283 Viral IAP-mediated preservation of the host IAP homolog capita

284 hortened the life span of a long-lived viral IAP (Op-IAP3) when fused to its N terminus.

285 teractions and is likely the result of viral IAP evolution in which degron-mediated destabilization a

286 We show here that the prototypical viral IAP, Op-IAP3, blocks apoptosis indirectly by associating

287 owever, the antiapoptotic mechanism of viral IAPs in host insects has been elusive.

288 t (BIR) domains and a C-terminal RING, viral IAPs use an unresolved mechanism to suppress apoptosis i

289 e dynamics of interference by selected viral IAPs, NS1 from Influenza A virus and NS3/4A from Hepatit

290 nation of these response motifs within viral IAPs, including those of baculoviruses, explains their u

291 bly methylated intracisternal A-particle (VM-IAP) epialleles as a model, we demonstrate that variable

292 finger protein (KZFP) genes that modifies VM-IAPs in trans in a sequence-specific manner.

293 red histone modifications at the targeted VM-IAPs.

294 We find that VM-IAPs cluster together phylogenetically and that this is

295 Hence, when IAPs are absent, LPS triggers RIPK3 to activate caspase-

296 e suggests higher incidence in Africa, where IAP is rare.

297 However, it is not known whether IAP induces autophagy.

298 However, while IAPs are derepressed in Dnmt1-ablated embryos and embryo

299 MOV10 also associated with IAP RNA.

300 tional MR imaging was highly concordant with IAP results, with up to 96% (22 of 23) accuracy, 96% (22

301 amined the association in risk of EOGBS with IAP coverage.

302 Also, feeding neonate larvae with IAP (inhibitor of apoptosis) or COP (COPI coatomer, beta